HR Execs on the Move

Bardavon

www.bardavon.com

 
Bardavon Health Innovations is a proactive Workers` Compensation partner that connects all stakeholders to better manage claims. We offer work readiness solutions through rehabilitation therapy. We share a holistic analysis of the claim so America`s injured workers can achieve optimized functional outcomes and return to full-duty.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.bardavon.com
  • 6803 West 64th Street Building 6, Suite 200
    Overland Park, KS USA 66202
  • Phone: 913.236.1020

Executives

Name Title Contact Details
Janel Wait
Chief Marketing Officer Profile
Natalie Berigan
Director of Product, Innovation Profile
Douglas Edwards
VP Product Research & Clinical Testing Profile
Pamela Landefeld
Chief Client Officer Profile
Douglas Dickerson
Senior Vice President of Software Products Profile

Similar Companies

Puritan's Pride

Puritan's Pride is a Bohemia, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smart Care Centers

Smart Care Centers is a Greenwood Village, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharmasol Corporation

Pharmasol Corporation is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Pharmasol Corporation is based in South Easton, MA. You can find more information on Pharmasol Corporation at www.pharmasol.com

Westmed Ambulance

Westmed Ambulance is a Baldwin Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.